帕瑞肽预防胰腺切除术后胰漏的成本效果分析(已撤稿)
该成本效果模型基于随机试验数据与2013年美国医院成本,比较胰腺切除术后预防性使用帕瑞肽与常规护理。虽使胰漏/脓肿发生率从21.9%降至9.2%,但每例患者费用从42,159美元增至77,202美元,每避免一例胰漏需花费301,628美元。
要点
- 预防性帕瑞肽使胰漏/脓肿发生率由21.9%降至9.2%。
- 含药费后每例患者总费用由42,159美元升至77,202美元。
- 每避免一例胰漏/脓肿的成本约为301,628美元。
核心结论
- 预防性使用帕瑞肽时,每避免一例胰漏/脓肿的成本约为30万美元。
研究设计与样本
- 成本效果模型,比较胰腺切除术后帕瑞肽与常规护理,概率来自近期随机试验,成本为2013年美国某大学胰腺病中心的医院成本。
主要发现
- 不考虑帕瑞肽药费时,预防性用药平均每例节省8,109美元。
- 计入药费后,每例患者费用从42,159美元增至77,202美元。
- 胰漏/胰瘘/脓肿(PF/PL/A)发生率从21.9%降至9.2%,相对降低56%。
- 每避免一例PF/PL/A的成本为301,628美元。
- 阈值分析显示,要使干预成本中性,帕瑞肽采购价(43,172美元)需降低92.3%至3,324美元,或药品报销需达39,848美元。
关键数值与推荐
- 围术期死亡率、PF/PL/A发生率和再入院率的敏感性分析未显著改变模型结果。
临床怎么用
- 广泛使用帕瑞肽需综合考量药品定价谈判、支付方报销、高用量使用及各方对降低并发症价值的共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pasireotide was recently shown to decrease leak rates after pancreatic resection, though the significant cost of the drug may be prohibitive. We conducted a cost-effectiveness analysis to determine whether prophylactic pasireotide possesses a reasonable cost profile by improving outcomes. METHODS: A cost-effectiveness model was constructed to compare pasireotide administration after pancreatic resection versus usual care, populated by probabilities of clinical outcomes from a recent randomized trial and hospital costs (2013 US$) from a university pancreatic disease center. Sensitivity analyses were performed to identify the most influential clinical components of the model. RESULTS: Without considering pasireotide cost, prophylactic use of the drug saved an average of $8,109 per patient. However, when the cost of pasireotide was included, per patient costs increased from $42,159 to $77,202. This was associated with a 56% reduction in pancreatic fistula/pancreatic leak/abscess (PF/PL/A) (21.9% to 9.2%). The resultant cost per PF/PL/A avoided was $301,628. Threshold analysis demonstrated that for this intervention to be cost neutral, either the purchase price of pasireotide ($43,172) must be reduced by 92.3% (to $3324) or drug reimbursement must be $39,848. Sensitivity analyses exploring variable perioperative mortality, rate of PF/PL/A, and readmission rates did not significantly alter model outcomes. CONCLUSIONS: Our analyses demonstrate that when prophylactic pasireotide is administered, the cost per PF/PL/A avoided is approximately $300,000. Aggressive pricing negotiation, payer reimbursement for the drug, high-volume use, and consensus among the public, payers, and surgical community regarding the value of reducing morbidity will ultimately determine the utility of widespread pasireotide application in pancreatic resection.
引用
- Abbott DE, Sutton JM, Jernigan PL, et al. How Much Should We Pay to Minimize Pancreatic Leak? The Cost-effectiveness of Pasireotide in Pancreatic Resection: RETRACTED. Ann Surg. 2016. PMID: 28045714. doi:10.1097/SLA.0000000000001411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。